FDA Modernization Act 3.0
Latest Action
Received in the Senate.
Official Summary
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
GovScope Watchdog™
AI Government Intelligence™The FDA Modernization Act 3.0 requires the Food and Drug Administration (FDA) to issue an interim final rule that implements a provision from the Consolidated Appropriations Act of 2023. This provision authorizes the use of alternatives to animal testing for investigational new drug applications. The rule must replace all references to animal testing with references to nonclinical testing methods in the FDA's regulations governing investigational new drug applications. The interim final rule must be published within one year of the bill's enactment and take immediate effect upon publication.
This bill mandates the FDA to update its regulations to prioritize non-animal testing methods for investigational new drugs by issuing an interim final rule within a year.
- Requires the FDA to publish an interim final rule replacing animal testing references with nonclinical testing alternatives in investigational new drug regulations.
- Implements a provision from the Consolidated Appropriations Act of 2023 related to alternatives to animal testing.
- The interim final rule must be published within one year of enactment and take immediate effect.
['Food and Drug Administration (FDA)', 'Pharmaceutical and biotechnology industries developing new drugs', 'Advocates for alternatives to animal testing', 'Researchers involved in drug development']
['The bill requires the FDA to issue an interim final rule within a strict one-year timeline, which may pose implementation challenges.', 'Replacing animal testing references with nonclinical alternatives may require significant regulatory adjustments and validation of alternative methods.', 'The immediate effect of the interim final rule could impact ongoing investigational new drug applications and regulatory processes.']
This bill follows a provision in the Consolidated Appropriations Act of 2023 that authorized alternatives to animal testing for investigational new drugs. It reflects ongoing legislative efforts to modernize FDA regulatory processes and incorporate scientific advancements in drug testing methodologies. The bill is currently in process, having been received in the Senate after originating in the House.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential acceleration of adoption and validation of alternative non-animal testing methods in drug development.', 'Possible changes in the regulatory review process that could affect timelines for investigational new drug applications.', 'Increased focus on scientific innovation in nonclinical testing methodologies within the pharmaceutical industry.']
The bill requires the FDA to issue an interim final rule within a fixed timeframe, which may limit opportunities for public comment before the rule takes effect. Oversight should monitor the FDA's compliance with the timeline and the adequacy of the rulemaking process, including how the agency validates and integrates nonclinical testing methods. Transparency in the transition from animal testing to alternative methods will be important to assess impacts on drug safety and efficacy evaluations.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.